The World Health Organization (WHO) has recommended a trial of the Ervebo vaccine in the Democratic Republic of the Congo (DRC) as the country reports over 4,000 confirmed Ebola cases. The recommendation comes after preliminary findings from animal studies suggested that Ervebo could offer some cross-protection against the Bundibugyo virus, which is responsible for the current outbreak (eastleighvoice.co.ke).
The Bundibugyo epidemic, now the world’s second-largest, has been described as the fastest-spreading on record. Health officials warn that the outbreak continues to grow, with new infections reported in multiple regions of the DRC. The WHO’s call for a vaccine trial marks a critical step in the global effort to contain the virus and protect vulnerable populations (aljazeera.com).
Ervebo, developed by the pharmaceutical company Bavarian Nordic, is already approved for use against the Zaire ebolavirus. The cross-protection hypothesis is based on research indicating that the vaccine may also be effective against related strains. Scientists are now working to determine if this potential benefit can be translated into real-world effectiveness during the ongoing outbreak.
